Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.

Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E, Hurt K, Hynes SM, Anthony SP, McKane S.

Invest New Drugs. 2013 Feb;31(1):136-44. doi: 10.1007/s10637-012-9815-9. Epub 2012 Apr 11.

2.

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.

Calvo E, Chen VJ, Marshall M, Ohnmacht U, Hynes SM, Kumm E, Diaz HB, Barnard D, Merzoug FF, Huber L, Kays L, Iversen P, Calles A, Voss B, Lin AB, Dickgreber N, Wehler T, Sebastian M.

Invest New Drugs. 2014 Oct;32(5):955-68. doi: 10.1007/s10637-014-0114-5. Epub 2014 Jun 20.

PMID:
24942404
3.

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.

Calvo E, Braiteh F, Von Hoff D, McWilliams R, Becerra C, Galsky MD, Jameson G, Lin J, McKane S, Wickremsinhe ER, Hynes SM, Bence Lin A, Hurt K, Richards D.

Oncology. 2016;91(5):251-260. Epub 2016 Sep 7.

PMID:
27598338
4.

Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.

Doi T, Yoshino T, Shitara K, Matsubara N, Fuse N, Naito Y, Uenaka K, Nakamura T, Hynes SM, Lin AB.

Anticancer Drugs. 2015 Nov;26(10):1043-53. doi: 10.1097/CAD.0000000000000278.

PMID:
26288133
5.

A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.

Ellis PM, Chu QS, Leighl N, Laurie SA, Fritsch H, Gaschler-Markefski B, Gyorffy S, Munzert G.

Clin Lung Cancer. 2013 Jan;14(1):19-27. doi: 10.1016/j.cllc.2012.04.003. Epub 2012 Jun 1.

PMID:
22658814
6.

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.

Chu QS, Sangha R, Hotte SJ, Sergenson G, Schnell D, Chand VK, Hirte HW.

Invest New Drugs. 2014 Dec;32(6):1226-35. doi: 10.1007/s10637-014-0139-9. Epub 2014 Jul 19.

PMID:
25037863
7.

Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.

Misset JL, Gamelin E, Campone M, Delaloge S, Latz JE, Bozec L, Fumoleau P.

Ann Oncol. 2004 Jul;15(7):1123-9.

PMID:
15205208
8.

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.

Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS.

Cancer Chemother Pharmacol. 2011 Aug;68(2):371-8. doi: 10.1007/s00280-010-1493-8. Epub 2010 Oct 27.

PMID:
20978761
9.

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.

Infante JR, Novello S, Ma WW, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, Ottesen LH, Burris HA 3rd, Adjei AA.

Invest New Drugs. 2013 Aug;31(4):927-36. doi: 10.1007/s10637-012-9900-0. Epub 2012 Nov 22.

PMID:
23179337
10.

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.

Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao RC, Camidge DR.

Cancer Chemother Pharmacol. 2012 Mar;69(3):709-22. doi: 10.1007/s00280-011-1755-0. Epub 2011 Oct 12.

11.

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.

Camidge DR, Blais N, Jonker DJ, Soulières D, Doebele RC, Ruiz-Garcia A, Thall A, Zhang K, Laurie SA, Chao RC, Chow LQ.

Cancer Chemother Pharmacol. 2013 Feb;71(2):307-19. doi: 10.1007/s00280-012-2008-6. Epub 2012 Oct 30.

PMID:
23108697
12.

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.

Blais N, Camidge DR, Jonker DJ, Soulières D, Laurie SA, Diab SG, Ruiz-Garcia A, Thall A, Zhang K, Chao RC, Chow LQ.

Invest New Drugs. 2013 Dec;31(6):1487-98. doi: 10.1007/s10637-013-0010-4. Epub 2013 Aug 22.

13.

A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.

Dittrich C, Petruzelka L, Vodvarka P, Gneist M, Janku F, Kysela T, Melemed A, Latz J, Simms L, Krejcy K.

Clin Cancer Res. 2006 Dec 1;12(23):7071-8.

14.

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

Rowinsky EK, Beeram M, Hammond LA, Schwartz G, De Bono J, Forouzesh B, Chu Q, Latz JE, Hong S, John W, Nguyen B.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):532-9.

15.

A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies.

Burris HA 3rd, Infante JR, Jewell RC, Spigel DR, Greco FA, Thompson DS, Jones SF.

Oncologist. 2010;15(9):954-60. doi: 10.1634/theoncologist.2010-0006. Epub 2010 Aug 26.

16.

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH.

J Clin Oncol. 2006 Feb 1;24(4):552-62. Epub 2006 Jan 3.

PMID:
16391300
17.

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.

Okamoto I, Shimizu T, Miyazaki M, Tsurutani J, Ichikawa Y, Terashima M, Takeda M, Fumita S, Ohki E, Kimura N, Hashimoto J, Nakagawa K.

Invest New Drugs. 2012 Apr;30(2):639-46. doi: 10.1007/s10637-010-9565-5. Epub 2010 Oct 20.

18.

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.

Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Aug;68(2):415-22. doi: 10.1007/s00280-010-1508-5. Epub 2010 Nov 11.

PMID:
21069335
19.

Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors.

Hanauske AR, Dumez H, Piccart M, Yilmaz E, Graefe T, Gil T, Simms L, Musib L, Awada A.

Invest New Drugs. 2009 Aug;27(4):356-65. doi: 10.1007/s10637-008-9193-5. Epub 2008 Oct 28.

PMID:
18956139
20.

Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.

Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR.

J Thorac Oncol. 2007 Dec;2(12):1112-6.

Supplemental Content

Support Center